Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take ...

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Eli Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) are set to seek a label expansion for their JAK inhibitor baricitinib, marketed ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by Clinical ...

The Hollywood star sat down with Newsweek to discuss his next big project: upping enrollment in clinical trials.

The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of ...

Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer ...